Experimentally induced animal models for cognitive dysfunction and Alzheimer's disease.
| Title: | Experimentally induced animal models for cognitive dysfunction and Alzheimer's disease. |
|---|---|
| Authors: | Rapaka D; A.U. College of Pharmaceutical Sciences, Andhra University, India.; Adiukwu PC; School of Pharmacy, University of Botswana, Gaborone, Botswana.; Bitra VR; School of Pharmacy, University of Botswana, Gaborone, Botswana. |
| Source: | MethodsX [MethodsX] 2022 Nov 24; Vol. 9, pp. 101933. Date of Electronic Publication: 2022 Nov 24 (Print Publication: 2022). |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101639829 Publication Model: eCollection Cited Medium: Print ISSN: 2215-0161 (Print) Linking ISSN: 22150161 NLM ISO Abbreviation: MethodsX Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam : Elsevier B.V., [2014]- |
| Abstract: | Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised pathologically by the presence of extracellular amyloid plaques and the intracellular neurofibrillary tangles, along with inflammation, and a compromised antioxidant system. Significant insights into the neurobiology to better understand the pathophysiology of AD and to evaluate the possibility of cutting-edge therapy strategies, can be obtained through the selection of a well-designed experimental animal model. From the transgenic to chemical/drug-induced models, none of them represents the complete picture of Alzheimer pathology and incidence of cognitive dysfunction. Researchers did not explain why one model was preferred over another, did not consider how the pathological phenomena were formed (spontaneously, experimentally, or by genetic manipulation), and did not address the traits of the species that affect the results. There is a lack of concordance between preclinical models and clinical trials that could be due to variety of reasons such as incomplete models, choice of animal species, lack of variability, and the validity of the models. To provide greater translation of preclinical AD studies to clinical trials proper designing of the model is essential. This review provides a brief recap ranging from animal doses to their induction mechanism and common limitations of the chemical-induced AD models. • Animal models may fail to replicate the exact pathology of the disease • Validity of the model is essential for proper translation of pathology from animal models to human disease • Appropriate induction doses need to be administered.; (© 2022 The Author(s).) |
| Competing Interests: | The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Authors declare no conflict of interest. |
| References: | J Neuroimmunol. 2016 Feb 15;291:115-24. (PMID: 26857505); Pharmacol Biochem Behav. 1983 Aug;19(2):177-85. (PMID: 6356170); Horm Behav. 2007 Sep;52(3):297-306. (PMID: 17583706); Neurosci Lett. 2010 Jan 18;469(1):88-92. (PMID: 19941937); Neurology. 1984 Jul;34(7):939-44. (PMID: 6610841); PLoS One. 2013;8(2):e56658. (PMID: 23437202); Front Mol Neurosci. 2018 Jan 17;10:429. (PMID: 29386992); J Ethnopharmacol. 2004 Apr;91(2-3):361-5. (PMID: 15120462); J Ethnopharmacol. 2007 Jul 25;112(3):552-6. (PMID: 17572029); Restor Neurol Neurosci. 2008;26(6):467-73. (PMID: 19096134); Neuroscience. 2011 Sep 29;192:322-33. (PMID: 21777659); J Pharm Pharmacol. 2013 Dec;65(12):1745-52. (PMID: 24236984); Psychopharmacology (Berl). 2006 Nov;188(4):597-604. (PMID: 16715255); Behav Neurosci. 1998 Oct;112(5):1199-208. (PMID: 9829797); Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):296-302. (PMID: 19146909); Pharmacol Res. 2021 Nov;173:105832. (PMID: 34450306); J Neurochem. 1990 Mar;54(3):1020-6. (PMID: 2303807); Neurosci Lett. 2006 Aug 14;404(1-2):176-81. (PMID: 16781062); Metab Brain Dis. 2022 Feb;37(2):343-357. (PMID: 35048324); J Alzheimers Dis. 2016;51(2):605-17. (PMID: 26890737); Biochim Biophys Acta. 2002 May 23;1582(1-3):144-53. (PMID: 12069822); Brain Res. 1995 Dec 8;702(1-2):233-45. (PMID: 8846082); J Alzheimers Dis. 2015;46(4):989-1005. (PMID: 25881906); Brain Res. 2001 Sep 7;912(2):128-36. (PMID: 11532428); J Mol Neurosci. 2004;24(1):97-104. (PMID: 15314257); Alcohol. 2019 Sep;79:127-135. (PMID: 30981808); Eur J Pharmacol. 2013 Jun 15;710(1-3):29-38. (PMID: 23588117); Rev Invest Clin. 2005 Jul-Aug;57(4):522-31. (PMID: 16315636); Neuropsychopharmacology. 2005 Oct;30(10):1861-9. (PMID: 15841110); Nat Rev Drug Discov. 2012 Feb 01;11(2):141-68. (PMID: 22293568); Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11065-9. (PMID: 12920183); Brain Res. 2009 Dec 8;1301:52-60. (PMID: 19765566); Phytomedicine. 2018 Mar 1;41:74-81. (PMID: 29519323); Life Sci. 2014 Jul 30;109(2):73-86. (PMID: 25066372); Alzheimers Dement. 2021 Mar;17(3):327-406. (PMID: 33756057); Int Immunopharmacol. 2019 Jul;72:48-54. (PMID: 30959371); Psicothema. 2009 Aug;21(3):471-4. (PMID: 19622331); Front Aging Neurosci. 2021 Nov 12;13:762659. (PMID: 34867289); Behav Brain Res. 2009 Dec 1;204(1):217-25. (PMID: 19527754); Cell Mol Neurobiol. 2008 Aug;28(5):781-94. (PMID: 17710534); Biochim Biophys Acta. 2013 Jan;1832(1):29-38. (PMID: 23036978); PLoS One. 2017 Aug 23;12(8):e0183565. (PMID: 28832656); Pharmazie. 2013 Nov;68(11):904-8. (PMID: 24380241); J Ayurveda Integr Med. 2019 Oct - Dec;10(4):241-247. (PMID: 30337026); Biomed Res Int. 2022 Feb 27;2022:7222590. (PMID: 35265716); Environ Sci Pollut Res Int. 2021 Apr;28(14):18134-18145. (PMID: 33405105); Brain Res. 1996 Jul 8;726(1-2):69-79. (PMID: 8836547); Neurobiol Learn Mem. 2008 May;89(4):441-7. (PMID: 18065245); Alcohol. 2013 Jun;47(4):309-16. (PMID: 23683528); Brain Res. 1977 Aug 5;131(1):184-90. (PMID: 560240); Pharmacol Rep. 2018 Apr;70(2):372-377. (PMID: 29477946); Brain Res. 2010 Nov 4;1359:233-46. (PMID: 20807517); Asian Pac J Trop Med. 2014 Sep;7S1:S278-81. (PMID: 25312136); Physiol Behav. 2016 Oct 15;165:383-91. (PMID: 27568232); Pharmacol Biochem Behav. 1997 Apr;56(4):583-7. (PMID: 9130281); Pharmacol Rep. 2007 May-Jun;59(3):274-83. (PMID: 17652827); Neurotox Res. 2021 Aug;39(4):1087-1102. (PMID: 33721210); Eur J Pharmacol. 2017 Nov 15;815:364-375. (PMID: 28978455); Neuropeptides. 2021 Dec;90:102196. (PMID: 34508923); Gen Hosp Psychiatry. 1987 Mar;9(2):154-5. (PMID: 3569890); Nat Med. 1998 Jul;4(7):827-31. (PMID: 9662375); Annu Rev Pharmacol Toxicol. 1986;26:161-81. (PMID: 3087271); Psychopharmacology (Berl). 2008 Dec;201(3):361-71. (PMID: 18758756); Int Immunopharmacol. 2020 Jun;83:106491. (PMID: 32279045); Brain Res Bull. 1989 Apr;22(4):599-603. (PMID: 2736389); Pharmacology. 1998 Jan;56(1):46-50. (PMID: 9467187); Eur J Pharmacol. 2019 Sep 15;859:172524. (PMID: 31291566); Neuropeptides. 2021 Aug;88:102151. (PMID: 33932860); J Agric Food Chem. 2011 Jun 8;59(11):6319-26. (PMID: 21548553); Neural Regen Res. 2017 Dec;12(12):2025-2034. (PMID: 29323042); Food Chem Toxicol. 2012 Mar;50(3-4):1036-44. (PMID: 22142688); Hippocampus. 2011 May;21(5):532-40. (PMID: 20865723); Oxid Med Cell Longev. 2010 Jan-Feb;3(1):13-22. (PMID: 20716924); Neurobiol Dis. 2021 Oct;158:105463. (PMID: 34363967); Pharmacol Biochem Behav. 1995 Sep;52(1):119-24. (PMID: 7501653); Indian J Med Res. 2008 Dec;128(6):744-51. (PMID: 19246799); Alcohol Clin Exp Res. 1998 May;22(3):628-36. (PMID: 9622443) |
| Contributed Indexing: | Keywords: Alzheimer's disease; Animal models; Induction dose; Validation |
| Entry Date(s): | Date Created: 20221208 Latest Revision: 20221210 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9720010 |
| DOI: | 10.1016/j.mex.2022.101933 |
| PMID: | 36479589 |
| Database: | MEDLINE |
Journal Article; Review